Insmed Inc at Citi BioPharma Conference (Virtual) Transcript
Hi. Good morning. Hi, It's [Navanty]. I cover spec pharma at Citi and today I have the pleasure of having Will Lewis, CEO of Insmed. Thanks a lot for joining us, Will.
Thanks for having me, Navan.
Questions & Answers
I'll just start with questions, if that's okay. So, maybe I'll start with the Japan launch for ARIKAYCE. How -- maybe if you could tell us how has it been going. Do you still expect to see an adoption curve similar to the U.S.?
Sure. So I think we're in an exciting time at the company, obviously, because we're now globally launched with ARIKAYCE for the treatment of refractory MAC NTM. And that indication is at varying degrees of prevalence around the world. Japan is particularly exciting because there it has the highest number of patients with refractory MAC NTM diagnosed anywhere,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
